



## **Retrophin Announces Voting Results of Special Meeting of Stockholders**

February 3, 2015

SAN DIEGO--(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced that at a Special Meeting of Stockholders held earlier today, the Company's stockholders voted to approve a proposal ratifying the prior issuance of stock options to purchase 1,928,000 shares of common stock and 230,000 restricted shares of common stock granted to employees between February 24, 2014 and August 18, 2014. Approximately 99.3% of votes present in person or by proxy at the meeting were cast in favor of the proposal.

The proposal described above was submitted for approval at the Special Meeting of Stockholders in order for Retrophin to regain compliance with Nasdaq Listing Rule 5635(c). Following the approval of the proposal at the Special Meeting of Stockholders, Retrophin believes that it has satisfied its obligations under the plan of compliance previously approved by Nasdaq.

### **About Retrophin**

Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. Retrophin's approved products include Chenodal®, Thiola® and Vecamyl®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), schizophrenia, infantile spasms, nephrotic syndrome and others. For additional information, please visit [www.retrophin.com](http://www.retrophin.com).

### **Forward-Looking Statements**

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. No forward-looking statement can be guaranteed. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. Retrophin undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in Retrophin's filings with the Securities and Exchange Commission.

Retrophin, Inc.  
Chris Cline, CFA, 646-564-3680  
Manager, Investor Relations  
[IR@retrophin.com](mailto:IR@retrophin.com)

Source: Retrophin, Inc.

News Provided by Acquire Media